Table of Contents
Journal of Sexually Transmitted Diseases
Volume 2016 (2016), Article ID 7684768, 10 pages
http://dx.doi.org/10.1155/2016/7684768
Review Article

New Biomedical Technologies and Strategies for Prevention of HIV and Other Sexually Transmitted Infections

Department of Internal Medicine, College of Health and Allied Sciences, The University of Dodoma, Dodoma, Tanzania

Received 21 June 2016; Revised 29 July 2016; Accepted 10 August 2016

Academic Editor: J. Gerardo Garcia-Lerma

Copyright © 2016 Bonaventura C. T. Mpondo. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. T. Da Ros and C. da Silva Schmitt, “Global epidemiology of sexually transmitted diseases,” Asian Journal of Andrology, vol. 10, no. 1, pp. 110–114, 2008. View at Publisher · View at Google Scholar
  2. World Bank, World Development Report: Investing in Health, The World Bank, New York, NY, USA, 1993. View at Publisher · View at Google Scholar
  3. J. A. Fernández-Romero, N. Teleshova, T. M. Zydowsky, and M. Robbiani, “Preclinical assessments of vaginal microbicide candidate safety and efficacy,” Advanced Drug Delivery Reviews, vol. 92, pp. 27–38, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Y. Barrow, C. Berkel, L. C. Brooks, S. L. Groseclose, D. B. Johnson, and J. A. Valentine, “Traditional sexually transmitted disease prevention and control strategies: tailoring for African American communities,” Sexually Transmitted Diseases, vol. 35, supplement, pp. S30–S39, 2008. View at Publisher · View at Google Scholar
  5. M. W. Adler, “Sexually transmitted diseases control in developing countries,” Genitourinary Medicine, vol. 72, no. 2, pp. 83–88, 1996. View at Google Scholar
  6. P. Mayaud and D. McCormick, “Interventions against sexually transmitted infections (STI) to prevent HIV infection,” British Medical Bulletin, vol. 58, pp. 129–153, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. H.-U. Bernard, R. D. Burk, Z. Chen, K. van Doorslaer, H. zur Hausen, and E. de Villiers, “Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments,” Virology, vol. 401, no. 1, pp. 70–79, 2010. View at Publisher · View at Google Scholar
  8. V. Bouvard, R. Baan, K. Straif et al., “A review of human carcinogens—part B: biological agents,” The Lancet Oncology, vol. 10, no. 4, pp. 321–322, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. H. zur Hausen, “Papillomaviruses and cancer: from basic studies to clinical application,” Nature Reviews Cancer, vol. 2, no. 5, pp. 342–350, 2002. View at Publisher · View at Google Scholar
  10. S. Franceschi, R. Herrero, G. M. Clifford et al., “Variations in the age-specific curves of human papillomavirus prevalence in women worldwide,” International Journal of Cancer, vol. 119, no. 11, pp. 2677–2684, 2006. View at Publisher · View at Google Scholar
  11. F. X. Bosch, A. Lorincz, N. Munoz, C. J. Meijer, and K. V. Shah, “The causal relation between human papillomavirus and cervical cancer,” Journal of Clinical Pathology, vol. 55, no. 4, pp. 244–265, 2002. View at Publisher · View at Google Scholar
  12. J. T. Schiller, X. Castellsagué, and S. M. Garland, “A review of clinical trials of human papillomavirus prophylactic vaccines,” Vaccine, vol. 30, supplement 5, pp. F123–F138, 2012. View at Publisher · View at Google Scholar
  13. D. M. Harper, E. L. Franco, C. Wheeler et al., “Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial,” The Lancet, vol. 364, no. 9447, pp. 1757–1765, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. L. L. Villa, K. A. Ault, A. R. Giuliano et al., “Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18,” Vaccine, vol. 24, no. 27-28, pp. 5571–5583, 2006. View at Publisher · View at Google Scholar
  15. R. De Vincenzo, C. Conte, C. Ricci, G. Scambia, and G. Capelli, “Long-term efficacy and safety of human papillomavirus vaccination,” International Journal of Women's Health, vol. 6, pp. 999–1010, 2014. View at Publisher · View at Google Scholar
  16. P. M. Day, R. C. Kines, C. D. Thompson et al., “In vivo mechanisms of vaccine-induced protection against HPV infection,” Cell Host & Microbe, vol. 8, no. 3, pp. 260–270, 2010. View at Publisher · View at Google Scholar
  17. E. Petrosky, J. A. Bocchini, S. Hariri et al., “Use of 9-valent human papillomavirus (HPV) vaccine: updated hpv vaccination recommendations of the advisory committee on immunization practices,” Morbidity and Mortality Weekly Report, vol. 64, no. 11, pp. 300–304, 2015. View at Google Scholar · View at Scopus
  18. J. Ferlay, H.-R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, “Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008,” International Journal of Cancer, vol. 127, no. 12, pp. 2893–2917, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. D. M. Parkin and F. Bray, “Chapter 2: the burden of HPV-related cancers,” Vaccine, vol. 24, supplement 3, pp. S3–S11-25, 2006. View at Publisher · View at Google Scholar
  20. K. Nanda, D. C. McCrory, E. R. Myers et al., “Accuracy of the papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review,” Annals of Internal Medicine, vol. 132, no. 10, pp. 810–819, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. T. C. Wright, L. S. Massad, C. J. Dunton, M. Spitzer, E. J. Wilkinson, and D. Solomon, “2006 Consensus guidelines for the management of women with abnormal cervical cancer screening tests,” American Journal of Obstetrics and Gynecology, vol. 197, no. 4, pp. 346–355, 2007. View at Publisher · View at Google Scholar
  22. T. C. Wright Jr., L. S. Massad, C. J. Dunton, M. Spitzer, E. J. Wilkinson, and D. Solomon, “2006 Consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ,” American Journal of Obstetrics and Gynecology, vol. 197, no. 4, pp. 340–345, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Ronco, P. Giorgi-Rossi, F. Carozzi et al., “Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial,” The Lancet Oncology, vol. 11, no. 3, pp. 249–257, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. N. Bulkmans, J. Berkhof, L. Rozendaal et al., “Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial,” The Lancet, vol. 370, no. 9601, pp. 1764–1772, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. M.-H. Mayrand, E. Duarte-Franco, I. Rodrigues et al., “Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer,” The New England Journal of Medicine, vol. 357, no. 16, pp. 1579–1588, 2007. View at Publisher · View at Google Scholar
  26. M. J. Khan, P. E. Castle, A. T. Lorincz et al., “The elevated 10-Year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice,” Journal of the National Cancer Institute, vol. 97, no. 14, pp. 1072–1079, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Dillner, M. Rebolj, P. Birembaut et al., “Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study,” The British Medical Journal, vol. 337, Article ID a1754, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Arbyn, P. Sasieni, C. J. L. M. Meijer, C. Clavel, G. Koliopoulos, and J. Dillner, “Chapter 9: clinical applications of HPV testing: a summary of meta-analyses,” Vaccine, vol. 24, supplement 3, pp. S3–78–89, 2006. View at Google Scholar
  29. A. E. Pettifor, H. V. Rees, I. Kleinschmidt et al., “Young people's sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey,” AIDS, vol. 19, no. 14, pp. 1525–1534, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. B. F. Haynes and R. J. Shattock, “Critical issues in mucosal immunity for HIV-1 vaccine development,” Journal of Allergy and Clinical Immunology, vol. 122, no. 1, pp. 3–9, 2008. View at Publisher · View at Google Scholar
  31. R. J. Shattock and J. P. Moore, “Inhibiting sexual transmission of HIV-1 infection,” Nature Reviews Microbiology, vol. 1, pp. 25–34, 2003. View at Publisher · View at Google Scholar
  32. Q. Abdool Karim, S. S. Abdool Karim, and J. Nkomokazi, “Sexual behaviour and knowledge of AIDS among urban black mothers. Implications for AIDS intervention programmes,” South African Medical Journal, vol. 80, no. 7, pp. 340–343, 1991. View at Google Scholar · View at Scopus
  33. O. Zambuko and A. J. Mturi, “Sexual risk behaviour among the youth in the era of HIV/AIDS in South Africa,” Journal of Biosocial Science, vol. 37, no. 5, pp. 569–584, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Gregson, C. A. Nyamukapa, G. P. Garnett et al., “Sexual mixing patterns and sex-differentials in teenage exposure to HIV infection in rural Zimbabwe,” The Lancet, vol. 359, no. 9321, pp. 1896–1903, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. Z. A. Stein, “HIV prevention: the need for methods women can use,” American Journal of Public Health, vol. 80, no. 4, pp. 460–462, 1990. View at Publisher · View at Google Scholar
  36. S. Skoler-Karpoff, G. Ramjee, K. Ahmed et al., “Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 372, no. 9654, pp. 1977–1987, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. P. J. Feldblum, A. Adeiga, R. Bakare et al., “SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria,” PLoS ONE, vol. 3, no. 1, Article ID e1474, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Van Damme, R. Govinden, F. M. Mirembe et al., “Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission,” The New England Journal of Medicine, vol. 359, no. 5, pp. 463–472, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. J. M. Marrazzo, G. Ramjee, B. A. Richardson et al., “Tenofovir-based preexposure prophylaxis for HIV infection among African women,” The New England Journal of Medicine, vol. 372, no. 6, pp. 509–518, 2015. View at Publisher · View at Google Scholar
  40. A. van der Straten, L. van Damme, J. E. Haberer, and D. R. Bangsberg, “Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention,” AIDS, vol. 26, no. 7, pp. F13–F19, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. M. B. Guffey, B. Richardson, M. Husnik et al., “HPTN 035 phase II/IIb randomised safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women,” Sexually Transmitted Infections, vol. 90, no. 5, pp. 363–369, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. D. C. Sokal, Q. A. Karim, S. Sibeko et al., “Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial,” Antiviral Therapy, vol. 18, no. 3, pp. 301–310, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. Q. Abdool Karim, S. S. Abdool Karim, J. A. Frohlich et al., “Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women,” Science, vol. 329, no. 5996, pp. 1168–1174, 2010. View at Publisher · View at Google Scholar
  44. E. De Clercq, “Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge,” Biochemical Pharmacology, vol. 73, no. 7, pp. 911–922, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. L. C. Rohan, B. J. Moncla, R. P. Kunjara Na Ayudhya et al., “In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide,” PLoS ONE, vol. 5, no. 2, Article ID e9310, 2010. View at Publisher · View at Google Scholar
  46. R. F. Baggaley, R. G. White, and M.-C. Boily, “HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention,” International Journal of Epidemiology, vol. 39, no. 4, pp. 1048–1063, 2010. View at Publisher · View at Google Scholar
  47. P. A. Anton, R. D. Cranston, A. Kashuba et al., “RMP-02/MTN-006: a phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate,” AIDS Research and Human Retroviruses, vol. 28, no. 11, pp. 1412–1421, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Cranage, S. Sharpe, C. Herrera et al., “Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel,” PLoS Medicine, vol. 5, article e157, 2008. View at Google Scholar
  49. J. G. García-Lerma, R. A. Otten, S. H. Qari et al., “Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir,” PLoS Medicine, vol. 5, no. 2, article e28, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. J. Lama, B. A. Richardson, A. Carballo-Diéguez et al., “McGowan I. MTN-017: rectal phase 2 extended safety and acceptability study of 1% tenofovir gel,” in Proceedings of the CROI Conference Expanding the Toolbox for Prevention, Seattle, Wash, USA, February 2016, http://www.croiconference.org/sessions/mtn-017-rectal-phase-2-extended-safety-and-acceptability-study-1-tenofovir-gel.
  51. J. M. Baeten, T. Palanee-Phillips, E. R. Brown et al., “Use of a vaginal ring containing dapivirine for HIV-1 prevention in women,” The New England Journal of Medicine, 2016. View at Publisher · View at Google Scholar
  52. A. Nel, S. Kapiga, L.-G. Bekker et al., “Safety and efficacy of dapivirine vaginal ring for HIV-1 prevention in African women,” in Proceedings of the CROI Conference, Boston, Mass, USA, February 2016.
  53. S. Garg, D. Goldman, M. Krumme, L. C. Rohan, S. Smoot, and D. R. Friend, “Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets,” Antiviral Research, vol. 88, pp. S19–S29, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. R. W. Buckheit, K. M. Watson, K. M. Morrow, and A. S. Ham, “Development of topical microbicides to prevent the sexual transmission of HIV,” Antiviral Research, vol. 85, no. 1, pp. 142–158, 2010. View at Publisher · View at Google Scholar
  55. A. S. Ham, M. R. Cost, A. B. Sassi, C. S. Dezzutti, and L. C. Rohan, “Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles,” Pharmaceutical Research, vol. 26, no. 3, pp. 502–511, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. C. McConville, D. R. Friend, M. R. Clark, and K. Malcolm, “Preformulation and development of a once-daily sustained-release tenofovir vaginal tablet tablet containing a single excipient,” Journal of Pharmaceutical Sciences, vol. 102, no. 6, pp. 1859–1868, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. L. E. Pereira, M. R. Clark, D. R. Friend et al., “Pharmacokinetic and safety analyses of tenofovir and tenofovir-emtricitabine vaginal tablets in pigtailed macaques,” Antimicrobial Agents and Chemotherapy, vol. 58, no. 5, pp. 2665–2674, 2014. View at Publisher · View at Google Scholar · View at Scopus
  58. K. E. Bunge, C. S. Dezzutti, I. Macio et al., “FAME-02: a phase I trial to assess safety, PK, and PD of gel and film formulations of dapivirine,” in Proceedings of the 21st CROI Conference, Boston, Mass, USA, 2014.
  59. A. Boasso, G. M. Shearer, and M. Clerici, “The hunt for an HIV vaccine: time to rethink recent failures,” The Lancet, vol. 371, no. 9628, pp. 1897–1898, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. H. Ledford, “HIV vaccine developers battle on, despite high-profile failures,” Nature Biotechnology, vol. 26, no. 6, pp. 591–592, 2008. View at Publisher · View at Google Scholar
  61. M. A. Trabaud, L. Cotte, J. L. Labernardière et al., “Variants with different mutation patterns persist in the quasispecies of enfuvirtide-resistant HIV-1 population during and after treatment in vivo,” Journal of Acquired Immune Deficiency Syndromes, vol. 46, no. 2, pp. 134–144, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. B. F. Haynes, J. Fleming, E. W. St Clair et al., “Immunology: cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies,” Science, vol. 308, no. 5730, pp. 1906–1908, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. G. Lucchese, A. Stufano, M. Calabro, and D. Kanduc, “Charting the peptide crossreactome between HIV-1 and the human proteome,” Frontiers in Bioscience, vol. 3, pp. 1385–1400, 2011. View at Google Scholar
  64. D. Kanduc, A. Stufano, G. Lucchese, and A. Kusalik, “Massive peptide sharing between viral and human proteomes,” Peptides, vol. 29, no. 10, pp. 1755–1766, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. M. I. Johnston and A. S. Fauci, “An HIV vaccine—evolving concepts,” The New England Journal of Medicine, vol. 356, no. 20, pp. 2073–2081, 2007. View at Publisher · View at Google Scholar
  66. N. Karasavvas, E. Billings, M. Rao et al., “The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120,” AIDS Research and Human Retroviruses, vol. 28, no. 11, pp. 1444–1457, 2012. View at Publisher · View at Google Scholar
  67. M. S. de Souza, S. Ratto-Kim, W. Chuenarom et al., “The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope,” The Journal of Immunology, vol. 188, no. 10, pp. 5166–5176, 2012. View at Publisher · View at Google Scholar
  68. S. Rerks-Ngarm, P. Pitisuttithum, S. Nitayaphan et al., “Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand,” The New England Journal of Medicine, vol. 361, no. 23, pp. 2209–2220, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. J. H. Kim, S. Rerks-Ngarm, J. Excler, and N. L. Michael, “HIV vaccines: lessons learned and the way forward,” Current Opinion in HIV and AIDS, vol. 5, no. 5, pp. 428–434, 2010. View at Publisher · View at Google Scholar
  70. T. C. Quinn, M. J. Wawer, N. Sewankambo et al., “Viral load and heterosexual transmission of human immunodeficiency virus type 1,” The New England Journal of Medicine, vol. 342, no. 13, pp. 921–929, 2000. View at Publisher · View at Google Scholar
  71. S. Attia, M. Egger, M. Müller, M. Zwahlen, and N. Low, “Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis,” AIDS, vol. 23, no. 11, pp. 1397–1404, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. M. S. Cohen, M. McCauley, and T. R. Gamble, “HIV treatment as prevention and HPTN 052,” Current Opinion in HIV and AIDS, vol. 7, no. 2, pp. 99–105, 2012. View at Publisher · View at Google Scholar
  73. S. A. Safren, K. H. Mayer, S.-S. Ou et al., “Adherence to early antiretroviral therapy: results from HPTN 052, a phase III, multinational randomized trial of ART to prevent HIV-1 sexual transmission in serodiscordant couples,” Journal of Acquired Immune Deficiency Syndromes, vol. 69, no. 2, pp. 234–240, 2015. View at Publisher · View at Google Scholar · View at Scopus
  74. World Health Organzation, Antiretroviral Treatment as Prevention (TASP) of HIV and TB, World Health Organzation, Geneva, Switzerland, 2012.
  75. R. M. Grant, J. R. Lama, P. L. Anderson et al., “Preexposure chemoprophylaxis for HIV prevention in men who have sex with men,” The New England Journal of Medicine, vol. 363, pp. 2587–2599, 2010. View at Publisher · View at Google Scholar
  76. J. M. Baeten, D. Donnell, P. Ndase et al., “Antiretroviral prophylaxis for HIV prevention in heterosexual men and women,” The New England Journal of Medicine, vol. 367, no. 5, pp. 399–410, 2012. View at Publisher · View at Google Scholar
  77. M. C. Thigpen, P. M. Kebaabetswe, L. A. Paxton et al., “Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana,” The New England Journal of Medicine, vol. 367, pp. 423–434, 2012. View at Publisher · View at Google Scholar
  78. J.-M. Molina, C. Capitant, B. Spire et al., “On-demand preexposure prophylaxis in men at high risk for HIV-1 infection,” The New England Journal of Medicine, vol. 373, no. 23, pp. 2237–2246, 2015. View at Publisher · View at Google Scholar · View at Scopus
  79. R. H. Graya, N. Kiwanuka, T. C. Quinn et al., “Male circumcision and HIV acquisition and transmission: cohort studies in Rakai, Uganda. Rakai Project Team,” AIDS, vol. 14, no. 15, pp. 2371–2381, 2000. View at Publisher · View at Google Scholar · View at Scopus
  80. H. A. Weiss, M. A. Quigley, and R. J. Hayes, “Male circumcision and risk of HIV infection in sub-Saharan Africa: a systematic review and meta-analysis,” AIDS, vol. 14, no. 15, pp. 2361–2370, 2000. View at Publisher · View at Google Scholar · View at Scopus
  81. J. M. Baeten, B. A. Richardson, L. Lavreys et al., “Female-to-male infectivity of HIV-1 among circumcised and uncircumcised Kenyan men,” Journal of Infectious Diseases, vol. 191, no. 4, pp. 546–553, 2005. View at Publisher · View at Google Scholar · View at Scopus
  82. B. Auvert, D. Taljaard, E. Lagarde, J. Sobngwi-Tambekou, R. Sitta, and A. Puren, “Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 trial,” PLoS Medicine, vol. 2, no. 11, article e298, 2005. View at Publisher · View at Google Scholar · View at Scopus
  83. R. H. Gray, G. Kigozi, D. Serwadda et al., “Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial,” The Lancet, vol. 369, no. 9562, pp. 657–666, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. R. C. Bailey, S. Moses, C. B. Parker et al., “Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial,” The Lancet, vol. 369, no. 9562, pp. 643–656, 2007. View at Publisher · View at Google Scholar · View at Scopus
  85. M. J. Wawer, F. Makumbi, G. Kigozi et al., “Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial,” The Lancet, vol. 374, no. 9685, pp. 229–237, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. A. A. R. Tobian, C. Gaydos, R. H. Gray et al., “Male circumcision and Mycoplasma genitalium infection in female partners: a randomised trial in Rakai, Uganda,” Sexually Transmitted Infections, vol. 90, pp. 150–154, 2014. View at Google Scholar
  87. A. A. Tobian, X. Kong, M. J. Wawer et al., “Circumcision of HIV-infected men and transmission of human papillomavirus to female partners: analyses of data from a randomised trial in Rakai, Uganda,” The Lancet Infectious Diseases, vol. 11, no. 8, pp. 604–612, 2011. View at Publisher · View at Google Scholar · View at Scopus
  88. M. E. Beksinska, G. Piaggio, J. A. Smit et al., “Performance and safety of the second-generation female condom (FC2) versus the Woman's, the VA worn-of-women, and the Cupid female condoms: a randomised controlled non-inferiority crossover trial,” The Lancet Global Health, vol. 1, no. 3, pp. E146–E152, 2013. View at Publisher · View at Google Scholar · View at Scopus
  89. D. W. Dowdy, M. D. Sweat, and D. R. Holtgrave, “Country-wide distribution of the nitrile female condom (FC2) in Brazil and South Africa: a cost-effectiveness analysis,” AIDS, vol. 20, no. 16, pp. 2091–2098, 2006. View at Publisher · View at Google Scholar · View at Scopus
  90. M. F. Gallo, M. Kilbourne-Brook, and P. S. Coffey, “A review of the effectiveness and acceptability of the female condom for dual protection,” Sexual Health, vol. 9, no. 1, pp. 18–26, 2012. View at Publisher · View at Google Scholar
  91. P. S. Coffey, M. Kilbourne-Brook, G. Austin, Y. Seamans, and J. Cohen, “Short-term acceptability of the PATH Woman's Condom among couples at three sites,” Contraception, vol. 73, no. 6, pp. 588–593, 2006. View at Publisher · View at Google Scholar · View at Scopus
  92. J. L. Schwartz, K. Barnhart, M. D. Creinin et al., “Comparative crossover study of the PATH Woman's Condom and the FC female Condom®,” Contraception, vol. 78, no. 6, pp. 465–473, 2008. View at Publisher · View at Google Scholar · View at Scopus
  93. S. Chapman, K. Jafa, K. Longfield et al., “Condom social marketing in sub-Saharan Africa and the Total Market Approach,” Sexual Health, vol. 9, no. 1, pp. 44–50, 2012. View at Publisher · View at Google Scholar · View at Scopus
  94. T. Chipfuwa, A. Manwere, M. M. Kuchenga et al., “Level of awareness and uptake of the female condom in women aged 18 to 49 years in Bindura district, Mashonaland Central province, Zimbabwe,” African Journal of AIDS Research, vol. 13, no. 1, pp. 75–80, 2014. View at Publisher · View at Google Scholar · View at Scopus
  95. World Health Organization, Guidelines on Post-Exposure Prophylaxis for HIV and the Use of Co-Trimoxazole Prophylaxis for HIV-Related Infections Among Adults, Adolescents and Children: Recommendations for a Public Health Approach: December 2014 Supplement to the 2013 Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection, World Health Organization, Geneva, Switzerland, 2014.
  96. J. G. García-Lerma, M.-E. Cong, J. Mitchell et al., “Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection,” Science Translational Medicine, vol. 2, no. 14, Article ID 14ra4, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. K. Nielsen-Saines, D. H. Watts, V. G. Veloso et al., “Three postpartum antiretroviral regimens to prevent intrapartum HIV infection,” The New England Journal of Medicine, vol. 366, no. 25, pp. 2368–2379, 2012. View at Publisher · View at Google Scholar
  98. D. M. Cardo, D. H. Culver, C. A. Ciesielski et al., “A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group,” The New England Journal of Medicine, vol. 337, pp. 1485–1490, 1997. View at Publisher · View at Google Scholar
  99. J. Bryant, L. Baxter, and S. Hird, “Non-occupational postexposure prophylaxis for HIV: a systematic review,” Health Technology Assessment, vol. 13, no. 14, 2009. View at Publisher · View at Google Scholar
  100. S. D. Pinkerton, J. N. Martin, M. E. Roland, M. H. Katz, T. J. Coates, and J. O. Kahn, “Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus,” Archives of Internal Medicine, vol. 164, no. 1, pp. 46–54, 2004. View at Publisher · View at Google Scholar · View at Scopus
  101. H. Ward and M. Rönn, “Contribution of sexually transmitted infections to the sexual transmission of HIV,” Current Opinion in HIV and AIDS, vol. 5, no. 4, pp. 305–310, 2010. View at Publisher · View at Google Scholar
  102. H. Grosskurth, J. Todd, E. Mwijarubi et al., “Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial,” The Lancet, vol. 346, no. 8974, pp. 530–536, 1995. View at Publisher · View at Google Scholar · View at Scopus
  103. M. J. Wawer, N. K. Sewankambo, D. Serwadda et al., “Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group,” The Lancet, vol. 353, no. 9152, pp. 525–535, 1999. View at Publisher · View at Google Scholar
  104. A. Kamali, M. Quigley, J. Nakiyingi et al., “Syndromic management of sexually-transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial,” The Lancet, vol. 361, no. 9358, pp. 645–652, 2003. View at Publisher · View at Google Scholar · View at Scopus
  105. R. Kaul, J. Kimani, N. J. Nagelkerke et al., “Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial,” The Journal of the American Medical Association, vol. 291, no. 21, pp. 2555–2562, 2004. View at Publisher · View at Google Scholar · View at Scopus
  106. R. G. White, K. K. Orroth, E. L. Korenromp et al., “Can population differences explain the contrasting results of the Mwanza, Rakai, and Masaka HIV/sexually transmitted disease intervention trials? A modeling study,” Journal of Acquired Immune Deficiency Syndromes, vol. 37, no. 4, pp. 1500–1513, 2004. View at Publisher · View at Google Scholar · View at Scopus
  107. H. Grosskurth, R. Gray, R. Hayes, D. Mabey, and M. Wawer, “Control of sexually transmitted diseases for HIV-1 prevention: understanding the implications of the Mwanza and Rakai trials,” The Lancet, vol. 355, no. 9219, pp. 1981–1987, 2000. View at Publisher · View at Google Scholar · View at Scopus
  108. P. Sangani, G. Rutherford, and D. Wilkinson, “Population-based interventions for reducing sexually transmitted infections, including HIV infection,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD001220, 2004. View at Google Scholar · View at Scopus
  109. D. C. Rijkaart, J. Berkhof, L. Rozendaal et al., “Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial,” The Lancet Oncology, vol. 13, no. 1, pp. 78–88, 2012. View at Publisher · View at Google Scholar · View at Scopus
  110. B. Grinsztejn, M. C. Hosseinipour, H. J. Ribaudo et al., “Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial,” The Lancet Infectious Diseases, vol. 14, no. 4, pp. 281–290, 2014. View at Publisher · View at Google Scholar
  111. J. M. Baeten, D. Donnell, P. Ndase et al., “Antiretroviral prophylaxis for HIV prevention in heterosexual men and women,” The New England Journal of Medicine, vol. 367, no. 5, pp. 399–410, 2012. View at Publisher · View at Google Scholar
  112. M. C. Thigpen, P. M. Kebaabetswe, L. A. Paxton et al., “Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in botswana,” The New England Journal of Medicine, vol. 367, no. 5, pp. 423–434, 2012. View at Publisher · View at Google Scholar
  113. S. McCormack, D. T. Dunn, M. Desai et al., “Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial,” The Lancet, vol. 387, no. 10013, pp. 53–60, 2016. View at Publisher · View at Google Scholar · View at Scopus